BioMarin Pharmaceutical Inc.
BMRN
$53.73
-$0.58-1.07%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -30.74M | 240.53M | 185.69M | 124.94M | 106.08M |
| Total Depreciation and Amortization | 18.49M | 18.56M | 22.07M | 23.61M | 19.01M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 262.02M | 84.25M | 57.10M | 120.23M | 57.33M |
| Change in Net Operating Assets | 118.93M | -158.07M | -90.46M | -83.15M | 39.06M |
| Cash from Operations | 368.69M | 185.27M | 174.39M | 185.63M | 221.48M |
| Capital Expenditure | -28.45M | -17.10M | -16.77M | -19.53M | -18.46M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -285.19M | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -17.32M | 4.51M | -11.47M | 95.93M | 2.31M |
| Cash from Investing | -330.96M | -12.59M | -28.24M | 76.40M | -16.16M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 0.00 | -494.99M |
| Issuance of Common Stock | 7.00K | 7.71M | -- | 7.86M | 4.80M |
| Repurchase of Common Stock | -2.18M | -12.31M | -38.78M | -4.91M | -5.91M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -94.00K | -3.02M |
| Cash from Financing | -2.17M | -4.60M | -38.78M | 2.86M | -499.13M |
| Foreign Exchange rate Adjustments | 739.00K | -3.06M | -1.42M | 2.50M | -2.90M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.29M | 165.01M | 105.96M | 267.39M | -296.70M |